Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 518 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,265.72. Following the completion of the transaction, the director now directly owns 128,585 shares in the company, valued at $3,541,230.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Enliven Therapeutics Stock Performance
Shares of ELVN opened at $25.51 on Friday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67. The business's 50 day moving average price is $23.20 and its two-hundred day moving average price is $21.86. The firm has a market cap of $1.20 billion, a PE ratio of -13.22 and a beta of 1.09.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.17. Research analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
Next opportunity for crypto millions
From Crypto 101 Media | Ad
The floodgates have opened.
Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto.
But most investors are missing the real goldmine…
Go here to discover the crypto that's about to leave Wall Street in the dust.
Institutional investors have recently modified their holdings of the company. Quest Partners LLC raised its position in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock worth $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock worth $140,000 after buying an additional 3,189 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics during the first quarter worth $167,000. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the third quarter worth $256,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics during the second quarter worth $322,000. 95.08% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Robert W. Baird assumed coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an "outperform" rating and a $32.00 price objective on the stock. Baird R W raised Enliven Therapeutics to a "strong-buy" rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday.
Check Out Our Latest Stock Report on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
